Insider Selling: Axon Enterprise (NASDAQ:AXON) Director Sells 100 Shares of Stock

Key Points

• Jeri Williams, a director at Axon Enterprise, sold 100 shares of stock for a total value of $75,254, resulting in a 6.60% decrease in their position.
• Axon reported earnings of $2.12 per share for the last quarter, surpassing estimates and showing a revenue increase of 32.6% year-over-year.
• Analyst ratings for Axon Enterprise vary, with thirteen analysts rating the stock as a Buy and a consensus target price of $837.69.

Axon Enterprise, Inc (NASDAQ:AXON - Get Free Report) Director Jeri Williams sold 100 shares of the stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $752.54, for a total value of $75,254.00. Following the sale, the director owned 1,416 shares of the company's stock, valued at approximately $1,065,596.64. The trade was a 6.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Axon Enterprise Stock Performance

NASDAQ:AXON traded up $4.66 during mid-day trading on Monday, hitting $760.79. 391,514 shares of the company's stock traded hands, compared to its average volume of 683,694. The firm has a 50 day moving average of $761.10 and a two-hundred day moving average of $688.38. Axon Enterprise, Inc has a 12 month low of $376.53 and a 12 month high of $885.91. The firm has a market capitalization of $59.72 billion, a price-to-earnings ratio of 187.85, a price-to-earnings-growth ratio of 27.75 and a beta of 1.40. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.58. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The firm had revenue of $668.54 million during the quarter, compared to the consensus estimate of $641.77 million. During the same quarter in the prior year, the company earned $1.20 EPS. The firm's revenue for the quarter was up 32.6% compared to the same quarter last year. Axon Enterprise has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Axon Enterprise

Hedge funds have recently modified their holdings of the stock. TCTC Holdings LLC raised its holdings in shares of Axon Enterprise by 75.0% in the 1st quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company's stock worth $29,000 after buying an additional 24 shares in the last quarter. Fourth Dimension Wealth LLC acquired a new position in shares of Axon Enterprise in the 4th quarter worth approximately $30,000. Bartlett & CO. Wealth Management LLC increased its holdings in Axon Enterprise by 132.0% during the 1st quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company's stock valued at $31,000 after purchasing an additional 33 shares in the last quarter. Banque Transatlantique SA acquired a new stake in Axon Enterprise during the 1st quarter valued at $31,000. Finally, Catalyst Capital Advisors LLC acquired a new stake in Axon Enterprise during the 1st quarter valued at $32,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Zacks Research downgraded Axon Enterprise from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 2nd. JPMorgan Chase & Co. upped their price target on Axon Enterprise from $730.00 to $850.00 and gave the company an "overweight" rating in a report on Thursday, July 17th. Craig Hallum raised Axon Enterprise from a "hold" rating to a "buy" rating and set a $900.00 price target for the company in a report on Tuesday, August 5th. JMP Securities upped their price target on Axon Enterprise from $725.00 to $825.00 and gave the company a "market outperform" rating in a report on Tuesday, July 22nd. Finally, Raymond James Financial reaffirmed an "outperform" rating and issued a $855.00 price target (up previously from $645.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Thirteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $837.69.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.